Elite in Lung Metastases

Matthias Guckenberger

Josef Schneider Str. 11, 
Wuerzburg, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Lung Metastases
Josef Schneider Str. 11, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Matthias Guckenberger practices in Wuerzburg, Germany. Mr. Guckenberger is rated as an Elite expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Metastases, Prostatectomy, and Cardiac Ablation.

His clinical research consists of co-authoring 576 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 19 articles in the study of Lung Metastases.

Gender
Male

Locations

Josef Schneider Str. 11, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
Enrollment Status: Recruiting
Publish Date: August 26, 2024
Intervention Type: Radiation
Study Phase: Not Applicable
Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial
Immune-modulatory Radiotherapy to Enhance the Effects of Neoadjuvant PD-L1 Blockade After Neoadjuvant Chemotherapy in Patients With Resectable Stage III(N2) Non-small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2025
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
A Multicentre Single-arm Phase II Trial Assessing the Safety and Efficacy of First-line Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Drug, Radiation
Study Drug: Osimertinib
Study Phase: Phase 2
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
Enrollment Status: Completed
Publish Date: August 24, 2022
Intervention Type: Drug
Study Phase: Phase 2
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Metformin
Study Phase: Phase 2
Radiotherapy and 6-month Androgen Deprivation Therapy With or Without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a Phase III Study
Radiotherapy and 6-month Androgen Deprivation Therapy With or Without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a Phase III Study
Enrollment Status: Withdrawn
Publish Date: August 17, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial
LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial
Enrollment Status: Unknown
Publish Date: January 31, 2020
Intervention Type: Radiation
Study Phase: Phase 2
View 6 Less Clinical Trials

576 Total Publications

Radiotherapy for Non-Malignant Diseases: An ASTRO-ESTRO-DEGRO-RANZCR White Paper.
Radiotherapy for Non-Malignant Diseases: An ASTRO-ESTRO-DEGRO-RANZCR White Paper.
Journal: International journal of radiation oncology, biology, physics
Published: September 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guckenberger's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 33 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile